Healius Limited (PGZ) AI Stock Analysis

• Market Cap: €343.35M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: DE
• Employees: 4,329
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 726,132,800
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: -0.18
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 3.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.68
• Price Target Upside: 58.14% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 7

Healius Limited Business Overview & Revenue Model

Company Description

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. It operates 2,105 pathology sites; 11 day hospital sites; and 134 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

How the Company Makes Money

Healius Limited Financial Statement Overview

Summary

Healius Limited faces significant profitability challenges with declining revenue growth and negative net profit margins, indicating financial distress. Despite a moderate balance sheet and some positive cash flow generation, the company's high leverage and negative return on equity raise concerns about financial risk and future sustainability.

Income Statement

Healius Limited has faced declining revenue, with a Revenue Growth Rate of 2.31% from 2023 to 2024, indicating stagnation compared to previous years. The Gross Profit Margin stands at 31.00% for 2024, showing some efficiency in generating profit from sales, but the Net Profit Margin is significantly negative at -36.98% due to substantial net losses, which is a red flag for profitability. The EBIT Margin of 3.75% reflects limited operating efficiency, while a negative EBITDA Margin suggests challenges in covering operating expenses without considering depreciation and amortization.

Balance Sheet

The Balance Sheet indicates a moderate level of financial stability. The Debt-to-Equity Ratio has increased to 1.53 in 2024, suggesting higher leverage and potential risk if earnings do not improve. However, the company maintains an Equity Ratio of 34.89%, indicating that a substantial portion of assets is financed by equity. Return on Equity is currently negative at -62.05%, highlighting the company's struggle to generate returns for shareholders amid net losses.

Cash Flow

Healius Limited demonstrates some strength in cash flow generation, with Operating Cash Flow to Net Income Ratio at -0.37, reflecting better cash flow management than net income suggests. The Free Cash Flow to Net Income Ratio is -0.27, indicating that despite net losses, the company is generating positive free cash flow. However, Free Cash Flow Growth Rate is negative at -24.54%, showing a decline in cash available for expansion and debt reduction.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
1.56B	1.75B	1.71B	2.29B	1.90B	1.56B
	Gross Profit
461.90M	1.52B	341.70M	779.20M	526.50M	343.60M
	EBIT
408.60M	65.50M	94.90M	474.10M	255.40M	86.10M
	EBITDA
77.80M	-298.10M	-57.80M	734.80M	470.40M	300.80M
	Net Income Common Stockholders
-22.80M	-645.80M	-374.60M	307.90M	43.70M	-70.50M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
85.70M	60.10M	115.30M	81.30M	70.10M	137.50M
	Total Assets
3.02B	2.98B	3.65B	4.14B	3.78B	4.59B
	Total Debt
1.62B	1.60B	1.77B	1.78B	1.44B	1.75B
	Net Debt
1.53B	1.54B	1.65B	1.70B	1.37B	1.61B
	Total Liabilities
1.97B	1.94B	2.15B	2.22B	1.92B	2.66B
	Stockholders Equity
1.05B	1.04B	1.51B	1.92B	1.86B	1.93B
Cash Flow		Free Cash Flow
292.70M	173.80M	230.30M	480.30M	432.00M	307.80M
	Operating Cash Flow
338.50M	237.80M	306.40M	573.80M	493.30M	380.20M
	Investing Cash Flow
-56.50M	-63.00M	67.30M	-401.70M	386.90M	-121.90M
	Financing Cash Flow
-251.40M	-259.00M	-339.70M	-163.50M	-952.10M	-233.60M

Healius Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGZ		€343.35M	―	-4.46%	―	―	―
SHL	72 Outperform	AU$12.68B	23.17	6.86%	4.05%	10.15%	6.20%
ACL	66 Neutral	AU$544.00M	18.00	18.39%	4.51%	7.80%	99.87%
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
IDX	51 Neutral	AU$864.04M	95.47	1.14%	2.50%	7.83%	―
MVF	48 Neutral	AU$290.28M	―	-0.87%	6.84%	14.24%	-109.59%
GSS	45 Neutral	AU$97.67M	―	-47.52%	―	44.61%	16.40%